Cue Biopharma, Inc. (CUE) 주식 분석

회사 개요

Cue Biopharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing a novel class of injectable therapeutics designed to selectively engage and modulate targeted, disease-relevant T cells within the United States. The company functions within the healthcare sector and specifically the biotechnology industry, positioning itself to leverage advancements in immunotherapy for treating various conditions. With a market capitalization of $28.60 million, annual revenue of $27.47 million, and a workforce of 29 employees, the firm maintains a lean operational structure typical of early-stage development entities. These financial metrics indicate that Cue Biopharma is a micro-cap entity with minimal revenue generation relative to its market valuation, suggesting that the majority of its market cap value is derived from the potential future success of its drug candidates rather than current cash flow operations.

재무 건전성

Cue Biopharma reported a trailing twelve-month revenue of $27.47 million, yet this generated a net income of $-26,602,000, highlighting a significant gap between top-line growth and profitability that reveals an aggressive cost structure associated with clinical trial expenditures and research and development activities. The company's EBITDA stood at $-25,563,000, while free cash flow was reported at $-9,951,750, indicating that the firm is currently burning cash to fund its operations and lacks the immediate financial flexibility to sustain itself without external capital raises or strategic partnerships. When analyzing the margins, the gross margin is negative at -26.9%, the operating margin is positive at 8.9%, and the profit margin is sharply negative at -96.9%, which collectively suggest that while the company is able to cover some operating costs, the cost of goods sold and research expenses are eroding profitability to a severe degree. On the liability side, the company holds $28.23 million in cash against $4.20 million in debt, resulting in a debt-to-equity ratio of 15.88, which implies a balance sheet that appears conservatively capitalized regarding absolute debt levels but carries high leverage relative to its equity base due to negative retained earnings. The current ratio stands at 2.74, indicating that the company possesses more than double the current assets needed to cover its short-term liabilities, thereby ensuring robust short-term liquidity despite the cash burn rate. Furthermore, the return on equity is -121.1% and the return on assets is -44.6%, metrics that reveal that management is currently diluting shareholder value and utilizing assets inefficiently to generate positive returns, a common but risky characteristic for clinical-stage biotech firms awaiting regulatory approval.

밸류에이션 평가

Valuation multiples for Cue Biopharma present a unique picture due to its lack of profitability, as the P/E ratio (TTM) is N/A and the forward P/E is negative at -0.61, implying that traditional earnings-based valuation models are not applicable and that the market is pricing the stock based on revenue potential or asset value rather than current earnings power. The price-to-book ratio is 1.07, suggesting that the market values the company at a slight premium over its book value, which may reflect intangible assets such as intellectual property and pipeline potential not fully captured on the balance sheet. Alternative valuation metrics like the price-to-sales ratio of 1.04 and an EV/EBITDA of -0.18 indicate that the company trades at a price roughly equal to its annual revenue, a multiple often seen in high-growth biotech firms where investors are willing to pay a premium for future commercialization prospects. Regarding trading range, the 52-week high is $1.03 and the 52-week low is $0.17, meaning the stock has experienced extreme volatility within this range, though the specific current price location relative to these bounds requires real-time data not provided in the static facts. The beta value of 1.58 indicates that the stock price is significantly more volatile than the broader market, moving 58% more than the market index on average, which reflects the high risk profile associated with small-cap biotechnology investments.

Growth & Income

Cue Biopharma has demonstrated explosive revenue growth with a year-over-year increase of 1292.3%, whereas earnings growth is N/A due to the company's substantial net losses, implying that revenue expansion is currently outpacing any notion of earnings accretion and that profitability is not yet a factor in the growth trajectory. As a non-dividend payer, the company offers a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm reinvests all available resources into research and development and clinical trials rather than distributing income to shareholders. This reinvestment strategy is critical for a clinical-stage company where capital allocation toward advancing the lead drug product candidate CUE-401 is the primary driver of future value creation. The overall growth and income profile is characterized by extremely high revenue expansion coupled with significant cash outflows and no dividend income, creating a high-risk, high-reward scenario dependent entirely on the clinical success of its pipeline.